Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE.
GENOPTIC vs NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed).
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic